SOLICITATION NOTICE
A -- NOTICE OF INTENT TO SOLE SOURCE A CONTRACT TO UNIVERSITY OF KANSAS, THERAPEUTIC PARTICLES AND BIOMATERIALS LABORATORY
- Notice Date
- 5/5/2014
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014
- ZIP Code
- 21702-5014
- Solicitation Number
- W81XWH-14-T-0211
- Response Due
- 5/19/2014
- Archive Date
- 7/4/2014
- Point of Contact
- Jessica Shives, 301-619-2322
- E-Mail Address
-
US Army Medical Research Acquisition Activity
(jessica.b.shives.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- Synopsis - Notice of Intent to Award Sole Source to the University of Kansas, Therapeutic Particles and Biomaterials Laboratory Date: 5 May 2014 Year: 2014 Contracting Office Zip Code: 21702-9232 Classification Code - 541712 - Research and Development Physical, Engineering, Life Sciences Contracting Office Address - US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 Subject: Notice of Intent to Sole Source a Contract to the University of Kansas, Therapeutic Particles and Biomaterials Laboratory; quote mark Formulation of Inhalable Therapeutic for the Treatment of Acute Pulmonary Melioidosis quote mark Solicitation Number: W81XWH-14-T-0211 Closing Response Date: Notice of Intent - 19 May 2014, Solicitation - 27 May 2014 (Solicitation will be posted on 19 May 2014). Contact Point: Jessica Shives at jessica.b.shives.civ@mail.mil Contract Award Dollar Amount: $63,000.00 over six months. Contract Award Date: 15 June 2014 Contractor: The University of Kansas, Therapeutic Particles and Biomaterials Laboratory Description: The U.S. Army Medical Research Institute of Infectious Disesases (USAMRIID) has a requirement to develop an inhalable formulation of the antibiotic ceftazidime for an animal study to investigate its therapeutic efficacy against acute pulmonary melioidosis, to include formulation, physicochemical characterization, and accelerated stability testing. The proposed contractor for this action is The University of Kansas, Therapeutic Particles and Biomaterials Lab under the leadership of Principle Investigator Cory Berkland. The University of Kansas, Therapeutic Particles and Biomaterials Lab is the only known existing source capable of fulfilling the Government's needs to obtain a NanoCluster drug nanoparticle colloid, which is thermodynamically driven into flocculates of drug nanoparticles (NanoClusters). The aerodynamic sizes of these flocculates must be customized for optimal delivery into different regions of the lungs (e.g. alveolar, bronchial, etc.). This particle engineering technology must have been successfully used to formulate locally acting and systemic therapeutics. The University of Kansas, Therapeutic Particles and Biomaterials Lab is the sole designer and developer of the NanoCluster technology and associated protocols and physicochemical characterization techniques. Therefore, they are the only vendor possessing the capability to provide the required formulated drug product and its physicochemical specifications required for USAMRIID research and development of an inhalable formulation of antibiotic to treat acute pulmonary melioidosis. The NanoCluster technology is not available from any other source. Place of Contract Performance - Fort Detrick, MD Set-aside Status: N/A
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/W81XWH-14-T-0211/listing.html)
- Place of Performance
- Address: US Army Medical Research Acquisition Activity ATTN: MCMR-AAA, 820 Chandler Street Frederick MD
- Zip Code: 21702-5014
- Zip Code: 21702-5014
- Record
- SN03357066-W 20140507/140505234415-54ef06341bd63cc24b1d509dd9d28eea (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |